TAK-915

TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC 50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment In Vivo TAK-915 (3 mg/kg; oral administration; daily; for 4 days; male F344 rats) treatment significantly reduces escape latency in aged rats in the Morris water maze task. TAK-915 (1, 3, and 10 mg/kg, p.o.) dose-dependently attenuates the non-selective muscarinic antagonist scopolamine-induced memory deficits in rats. Oral dosing of TAK-915 (compound 36) (3 or 10 mg/kg) in mice produces a dose-dependent increase in 3',5'-cyclic guanosine monophosphate (cGMP) levels, with significant cGMP increases observed at a dose of 10 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male F344 rats (10-week-old and 26-month-old) bearing morris water maze taskDosage: 3 mg/kg Administration: Oral administration; daily; for 4 days Result: Significantly reduced escape latency in aged rats in the Morris water maze task. Form:Solid IC50& Target:PDE2A 0.61 nM (IC 50 ) PDE1A 2497 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet